GW0742

Cat. No.:	HY-13928		
CAS No.:	317318-84-6		
Molecular Formula:	C ₂₁ H ₁₇ F ₄ NO ₃ S	5 ₂	
Molecular Weight:	471.49		
Target:	PPAR		
Pathway:	Cell Cycle/DNA Damage; Vitamin D Related/Nuclear Receptor		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year

SOLVENT & SOLUBILITY

In Vitro	DMSO : ≥ 34 mg/mL (72.11 mM) * "≥" means soluble, but saturation unknown.				
		Solvent Mass Concentration	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.1209 mL	10.6047 mL	21.2094 mL
		5 mM	0.4242 mL	2.1209 mL	4.2419 mL
		10 mM	0.2121 mL	1.0605 mL	2.1209 mL
	Please refer to the solubility information to select the appropriate solvent.				
In Vivo	 Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.30 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.30 mM); Clear solution 				

BIOLOGICAL ACTIV	ΙТΥ ————————————————————————————————————		
Description	GW0742 is a potent PPARβ and	d PPARδ agonist, with an IC ₅₀ of	1 nM for human PPARδ in binding assay, and EC ₅₀ s of 1 nM, 1.1
	μM and 2 μM for human PPAR	δ, PPARα, and PPARγ, respective	εly.
IC₅₀ & Target	ΡΡΑRδ	PPARα	ΡΡΑRγ
	1 nM (EC50)	1.1 μM (EC50)	2 μΜ (EC50)
In Vitro	GW0742 is a potent PPARβ and PPARδ agonist, with an IC ₅₀ of 1 nM for human PPARδ, and EC ₅₀ s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ respectively ^[1] . GW0742 (100 μM) activates human PPARα and mouse PPARβ in MCF-7 cells. GW0742 (100 μM) significantly reduces low-KCl-induced apoptosis of cerebellar granule neurons. GW0742 shows no		

Product Data Sheet

F - S - S - S - O - OH



	obvious inherent toxicity on cerebellar granule neuronal cells after treatment of 3-100 μM for 24 h, but induces increased cell death at 100 μM after 48 hr of treatment. Moreover, GW0742 (100 μM) increases c-Jun expression in cerebellar granule neuron cultures observed at 6 hr ^[2] . GW0742 (1 μM) induces PPARδ protein in neonatal rat cardiomyocytes. GW0742 also raises mRNA levels of long-chain acyl-CoA dehydrogenase (LCAD), very long-chain acyl-CoA dehydrogenase (VLCAD), acyl-CoA oxidase 1 (ACOX1), uncoupling protein 3 (UCP3), malonyl-CoA decarboxylase (MCD), and pyruvate dehydrogenase kinase 4 (PDK4) in neonatal rat cardiomyocytes ^[4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	GW0742 (0.3 mg/kg, i.p.) reduces intensity masson-trichrome staining, and attenuates the histological signs in bleomycin instillatio (BLEO)-induced lung injury of mice. GW0742 (0.3 mg/kg, i.p.) also causes a reduction of the BLEO-induced loss body weight, and a decrease of myeloperoxidase (MPO) activity. GW0742 shows significant inhibition of TNF-a and IL-1β in instilled-mice. GW0742 prevents bleomycin-induced IkB-a degradation, reduces the levels of NF-kB p65 in the lung, and decreases iNOS and p-ERK expression in BLEO-induced mice ^[3] . GW0742 (5 mg/kg/day, i.v.) increases PPARδ protein level in the heart of rats. GW0742 also induces the increase in LCAD, VLCAD, and ACOX1 in the heart of rats ^[4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

DRATACAL	
Cell Assay ^[2]	The PPARβ activator GW0742 and the RXR activator 9-cis-retinoic acid are dissolved in DMSO. The final DMSO concentration des not exceed 0.5% v/v, and this concentration is used in control wells. For each culture plate, one row of wells is treated with 500 μM glutamate. These wells serve as a positive control and for normalisation of data. Cell death (toxicity) is assessed by using an assay designed to measure lactate dehydrogenase (LDH) release ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[3]	Male CD mice (25-35 g) are housed in a controlled environment and provided with standard rodent chow and water. Mice are randomized into four experimental groups: bleomycin-treated group: mice are subjected to lung injury induced by intratracheal instillation of bleomycin and treated daily via intraperitoneal injection with vehicle of GW0742 (10% dimethylsulfoxide (OMSO, 1 mL/kg), 1 h after BLEO instillation (n = 15). GW0742 group: identical to bleomycin-treated group but mice are treated daily with GW0742 (0.3 mg/kg, 1h after BLEO instillation) via intraperitoneal injection (n = 15). Shamoperated mice + vehicle group: animals are subjected to the identical surgical procedure but receive intratracheal instillation of saline (0.9%) instead of BLEO and are treated daily with the vehicle of GW0742 (10% dimethylsulfoxide (DMSO), 1 mL/kg, i.p.), 1 h after saline instillation (n = 15). Shamoperated mice + GW0742 group: identical to sham + vehicle group but mice are treated daily with GW0742 (0.3 mg/kg, 1 h after saline instillation) via intraperitoneal injection (n = 15). MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Biol Psychiatry. 2021 Mar 15;89(6):615-626.
- Pharmacol Res. 2020 Mar;153:104679.
- Br J Pharmacol. 2020 May;177(10):2286-2302.
- Eur J Med Chem. 5 February 2022, 114061.
- Eur J Med Chem. 2021 Aug 25;225:113807.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Sznaidman ML, et al. Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity. Bioorg Med Chem Lett. 2003 May 5;13(9):1517-21.

[2]. Smith SA, et al. Effect of the peroxisome proliferator-activated receptor beta activator GW0742 in rat cultured cerebellar granule neurons. J Neurosci Res. 2004 Jul 15;77(2):240-9.

[3]. Galuppo M, et al. GW0742, a high affinity PPAR-β/δ agonist reduces lung inflammation induced by bleomycin instillation in mice. Int J Immunopathol Pharmacol. 2010 Oct-Dec;23(4):1033-46.

[4]. Kuo SC, et al. Activation of receptors δ (PPARδ) by agonist (GW0742) may enhance lipid metabolism in heart both in vivo and in vitro. Horm Metab Res. 2013 Nov;45(12):880-6.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA